FDA’s March 2026 rare-disease approvals: what families should know

Families facing ultra-rare diseases got a notable run of FDA decisions in March 2026. On March 25, the agency approved Avlayah for neurologic manifestations of Hunter syndrome. On March 10, it approved Wellcovorin for cerebral folate transport deficiency tied to confirmed FOLR1 variants. And on January 12, the FDA approved Zycubo for children with Menkes disease. In each case, the approvals mattered because they offered treatment options where choices had been extremely limited.

That does not mean these medicines are cures. In rare diseases, approvals often rest on small studies, single-arm trials, open-label designs, or external control groups. Those approaches can be appropriate when a disease is ultra-rare and serious, but they also mean the benefit is not as certain as it would be in a large randomized trial. Families should think of these approvals as important advances that may help some patients while still requiring careful monitoring and realistic expectations.

What changed

Avlayah was approved on March 25, 2026, for neurologic manifestations of Hunter syndrome, also called mucopolysaccharidosis type II. The FDA said the approval was supported by a phase 1/2, multi-cohort, single-arm, open-label trial in 47 pediatric patients ages 3 months to 13 years.

Wellcovorin was approved on March 10, 2026, for cerebral folate deficiency in adults and children who have a confirmed FOLR1 gene variant. The FDA said this was the first treatment for the rare genetic condition and that the decision relied on a systematic review of published literature, patient-level case reports, and mechanistic data.

Zycubo was approved on January 12, 2026, as the first treatment for children with Menkes disease. The FDA said the evidence came from two open-label, single-arm clinical trials, with survival compared against contemporaneous external control groups.

Why these approvals matter

Rare-disease families often face a hard tradeoff: the condition may be severe and progressive, but the research base is small because so few patients exist. In that setting, even a first approved treatment can matter a great deal for symptoms, survival, or day-to-day function.

The March approvals also show how the FDA sometimes acts on less traditional evidence when a disease is serious, the patient population is tiny, and unmet need is high. That flexibility can speed access, but it also means families need to pay close attention to what the studies did and did not prove.

What the evidence looked like

These approvals were not based on large randomized trials. Avlayah’s supporting study was single-arm and open-label, which means everyone received the drug and neither patients nor investigators were blinded. That can be useful in a rare disease, but it makes it harder to know how much improvement came from the drug versus the natural course of illness or other care.

Wellcovorin’s approval relied heavily on a literature review and mechanistic evidence rather than a conventional new-drug trial. That can be reasonable for an ultra-rare condition, but it also means the evidence is less direct than results from a large controlled study.

Zycubo used external control data, which compares treated patients with untreated patients drawn from other sources. This can be the best available option when a placebo trial is not practical, but the comparison is still less definitive than a randomized trial.

What families should keep in mind

These approvals may offer real benefit, especially when no previous FDA-approved option existed. But they are still treatments for serious diseases, not cures, and they do not remove the need for specialty care, developmental support, and close follow-up for side effects or disease progression.

Access can also be complicated. Rare-disease drugs often require specialty prescribers, prior authorization, genetic confirmation, and coordinated monitoring. Insurance coverage, infusion or injection logistics, and out-of-pocket costs can vary by plan and by state.

For Avlayah, the FDA notes a boxed warning for allergic reactions, including anaphylaxis, and recommends starting therapy in a health care setting with appropriate monitoring. The agency also says hemoglobin, kidney function, and urine protein should be monitored. Zycubo carries a need for close monitoring for copper toxicity, while Wellcovorin’s labeled use is limited to patients with confirmed FOLR1-related disease.

What’s still uncertain

For all three drugs, questions remain about how long benefits last, which patients benefit most, how the medicines work across different ages and disease stages, and how safety looks over time outside a trial setting. Those are common open questions in rare-disease medicine, where follow-up data are often limited at the time of approval.

For Wellcovorin in particular, the FDA approval was for cerebral folate deficiency with a confirmed FOLR1 variant. That is not the same as a broad treatment claim for every child with developmental delay or every patient discussed online in connection with folinic acid.

The broader pipeline is still moving

These approvals were not the only rare-disease development news in spring 2026. On May 8, 2026, the FDA cleared an investigational new drug application for MMA-101, a gene-therapy candidate for methylmalonyl-CoA mutase methylmalonic acidemia. NCATS said the clearance allows a first-in-human Phase I/II trial to move forward at the NIH Clinical Center.

That matters because it shows the pipeline is still active even for diseases that have long had few options. For families, it is a reminder that rare-disease progress often comes one approval, one trial, and one patient group at a time.

Questions families can bring to a clinician

Is the diagnosis the exact condition named in the FDA approval?
What benefits were seen in the studies, and how strong was the evidence?
What side effects or monitoring are most important for this medicine?
How is access handled through our insurance plan or specialty pharmacy?
Should supportive therapies or follow-up tests continue even if treatment starts?

The bottom line: March 2026 was an unusually active month for rare-disease approvals, and that is good news for families who have waited a long time for options. But the evidence behind these drugs reflects the realities of ultra-rare disease research, so the next step is careful, individualized discussion with a specialist—not assumptions that a new approval solves everything.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.